Total Payments
$314,462
2024 Payments
$61,652
Companies
15
Transactions
225
Medicare Patients
183
Medicare Billing
$30,187
Payment Breakdown by Category
Consulting$172,488 (54.9%)
Other$74,589 (23.7%)
Travel$31,969 (10.2%)
Research$24,723 (7.9%)
Education$7,225 (2.3%)
Food & Beverage$3,468 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $172,488 | 49 | 54.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $49,326 | 32 | 15.7% |
| Travel and Lodging | $31,969 | 49 | 10.2% |
| Honoraria | $25,263 | 5 | 8.0% |
| Unspecified | $24,723 | 15 | 7.9% |
| Education | $7,225 | 3 | 2.3% |
| Food and Beverage | $3,468 | 72 | 1.1% |
Payments by Type
General
$289,739
210 transactions
Research
$24,723
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $95,142 | 90 | $0 (2024) |
| PFIZER INC. | $92,142 | 41 | $0 (2024) |
| AbbVie Inc. | $74,941 | 61 | $0 (2023) |
| Eli Lilly and Company | $20,250 | 4 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $13,214 | 4 | $0 (2024) |
| Janssen Biotech, Inc. | $8,558 | 12 | $0 (2024) |
| Celgene Corporation | $2,450 | 1 | $0 (2020) |
| Janssen Global Services, LLC | $2,100 | 1 | $0 (2021) |
| Celltrion USA Inc. | $2,050 | 2 | $0 (2023) |
| Takeda Pharmaceutical Company, Limited | $2,030 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $61,652 | 22 | PFIZER INC. ($29,285) |
| 2023 | $67,963 | 37 | AbbVie Inc. ($44,317) |
| 2022 | $49,642 | 42 | ABBVIE INC. ($29,066) |
| 2021 | $29,527 | 15 | PFIZER INC. ($17,518) |
| 2020 | $21,750 | 10 | PFIZER INC. ($16,340) |
| 2019 | $47,489 | 52 | Takeda Pharmaceuticals U.S.A., Inc. ($32,367) |
| 2018 | $17,825 | 26 | Takeda Pharmaceuticals U.S.A., Inc. ($11,876) |
| 2017 | $18,614 | 21 | Takeda Pharmaceuticals U.S.A., Inc. ($17,055) |
All Payment Transactions
225 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | VELSIPITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,081.50 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 12/03/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 10/22/2024 | PFIZER INC. | VELSIPITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,442.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 09/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Consulting Fee | Cash or cash equivalent | $4,745.20 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Consulting Fee | Cash or cash equivalent | $4,745.20 | General |
| Category: INTERNAL MEDICINE | ||||||
| 05/24/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $3,400.00 | General |
| Category: Immunology | ||||||
| 05/20/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,163.46 | General |
| Category: INTERNAL MEDICINE | ||||||
| 05/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $149.18 | General |
| Category: Immunology | ||||||
| 05/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $32.00 | General |
| Category: Immunology | ||||||
| 04/26/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $5,422.50 | General |
| 04/22/2024 | PFIZER INC. | VELSIPITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,836.50 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 03/15/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $200.68 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 03/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,745.20 | General |
| Category: INTERNAL MEDICINE | ||||||
| 03/06/2024 | PFIZER INC. | VELSIPITY (Drug) | Consulting Fee | Cash or cash equivalent | $16,400.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 02/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,163.46 | General |
| Category: INTERNAL MEDICINE | ||||||
| 02/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 01/27/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $31.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 01/26/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $6.52 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 01/18/2024 | PFIZER INC. | VELSIPITY (Drug) | Travel and Lodging | In-kind items and services | $4,186.20 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 01/18/2024 | PFIZER INC. | VELSIPITY (Drug) | Travel and Lodging | In-kind items and services | $561.98 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 01/18/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $185.06 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 01/09/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/15/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $130.10 | General |
| Category: Immunology | ||||||
| 12/15/2023 | AbbVie Inc. | — | Food and Beverage | In-kind items and services | $40.89 | General |
| 10/19/2023 | AbbVie Inc. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,070 | 5 |
| A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease | ABBVIE INC. | $1,673 | 6 |
| TOFACITINIB IBD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,400 | 1 |
| VELSIPITY CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 15 | 24 | $7,440 | $1,900 |
| 2022 | 3 | 64 | 66 | $63,350 | $10,754 |
| 2021 | 4 | 70 | 77 | $80,240 | $10,933 |
| 2020 | 2 | 34 | 48 | $32,040 | $6,600 |
Total Patients
183
Total Services
215
Medicare Billing
$30,187
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 15 | 24 | $7,440 | $1,900 | 25.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 36 | 36 | $28,800 | $7,010 | 24.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 17 | 17 | $32,470 | $3,239 | 10.0% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 11 | 13 | $2,080 | $505.95 | 24.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 30 | 31 | $24,800 | $5,763 | 23.2% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 13 | 13 | $24,830 | $2,071 | 8.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 14 | 20 | $8,900 | $1,701 | 19.1% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 13 | 13 | $21,710 | $1,399 | 6.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 20 | 20 | $15,800 | $3,680 | 23.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 14 | 28 | $16,240 | $2,920 | 18.0% |
About Ryan Ungaro
Ryan Ungaro is a Gastroenterology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/01/2009. The National Provider Identifier (NPI) number assigned to this provider is 1790927150.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ryan Ungaro has received a total of $314,462 in payments from pharmaceutical and medical device companies, with $61,652 received in 2024. These payments were reported across 225 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($172,488).
As a Medicare-enrolled provider, Ungaro has provided services to 183 Medicare beneficiaries, totaling 215 services with total Medicare billing of $30,187. Data is available for 4 years (2020–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location New York, NY
- Active Since 04/01/2009
- Last Updated 02/22/2019
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1790927150
Products in Payments
- Entyvio (Biological) $51,971
- XELJANZ (Drug) $39,724
- ENTYVIO (Biological) $38,683
- VELSIPITY (Drug) $29,224
- ZEPOSIA (Drug) $11,544
- SKYRIZI (Biological) $10,400
- RINVOQ (Biological) $7,939
- TREMFYA (Drug) $6,131
- SKYRIZI (Drug) $2,363
- STELARA (Biological) $2,328
- ZYMFENTRA (Biological) $2,050
- HUMIRA (Biological) $1,135
- EUCRISA (Drug) $960.00
- INFLECTRA (Biological) $960.00
- Humira (Biological) $306.45
- REMICADE (Biological) $98.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in New York
Arthur Kornbluth, Md, MD
Gastroenterology — Payments: $2.4M
Gastroenterology $2.4M
Dr. David Carr-Locke, Md Frcp Facg Masge, MD FRCP FACG MASGE
Gastroenterology — Payments: $2.3M
Gastroenterology $2.3M
Jean-Frederic Colombel, M.d, M.D
Gastroenterology — Payments: $1.1M
Gastroenterology $1.1M
Dr. Bruce Sands, Md, MD
Gastroenterology — Payments: $1.0M
Gastroenterology $1.0M
Ellen Scherl, Md, MD
Gastroenterology — Payments: $880,329
Gastroenterology $880,329
Sonal Kumar, Md, MD
Gastroenterology — Payments: $769,554
Gastroenterology $769,554